{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:12:47Z","timestamp":1788279167797,"version":"build-2803163510"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Clinical Research Program of Air Force Medical University","award":["2022LC2205"],"award-info":[{"award-number":["2022LC2205"]}]},{"name":"the Discipline Promotion Program of Xijing Hospital","award":["XJZT24LY45"],"award-info":[{"award-number":["XJZT24LY45"]}]},{"name":"the Graduate Research Fund of Xijing Hospital","award":["2025SZ010, XT2023E2043"],"award-info":[{"award-number":["2025SZ010, XT2023E2043"]}]},{"name":"he Key Research and Development Program of Shaanxi Province","award":["2023-YBSF-429; 2024SF2-GJHX-08"],"award-info":[{"award-number":["2023-YBSF-429; 2024SF2-GJHX-08"]}]},{"name":"the Science and Technology Program of the Public Health Research Joint Fund for Public Hospitals of Inner Mongolia Academy of Medical Sciences","award":["2025GLLH0437"],"award-info":[{"award-number":["2025GLLH0437"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08736-4","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:12:03Z","timestamp":1785409923000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PPAR\u03b3 suppresses the tumorigenesis of retroperitoneal liposarcoma via inactivation of the PI3K\/AKT signaling pathway"],"prefix":"10.1186","volume":"24","author":[{"given":"Niu","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juzheng","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaojie","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haohao","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuqiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqiang","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"issue":"1","key":"8736_CR1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/PAP.0000000000000284","volume":"28","author":"JH Choi","year":"2021","unstructured":"Choi JH, Ro JY. The 2020 WHO Classification of Tumors of Soft Tissue: Selected Changes and New Entities. Adv Anat Pathol. 2021;28(1):44\u201358.","journal-title":"Adv Anat Pathol"},{"issue":"2","key":"8736_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.32074\/1591-951X-213","volume":"113","author":"M Sbaraglia","year":"2021","unstructured":"Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives. Pathologica. 2021;113(2):70\u201384.","journal-title":"Pathologica"},{"issue":"22","key":"8736_CR3","doi-asserted-by":"publisher","first-page":"5469","DOI":"10.3390\/cancers15225469","volume":"15","author":"E De Bree","year":"2023","unstructured":"De Bree E, Michelakis D, Heretis I, et al. Retroperitoneal Soft Tissue Sarcoma: Emerging Therapeutic Strategies. Cancers (Basel). 2023;15(22):5469.","journal-title":"Cancers (Basel)"},{"key":"8736_CR4","doi-asserted-by":"publisher","first-page":"e948952","DOI":"10.12659\/AJCR.948952","volume":"26","author":"N Dai","year":"2025","unstructured":"Dai N, Yuan J, Wang X, et al. Giant Intra-Abdominal Tumor, Compatible with Liposarcoma: A Case Report and Literature Review. Am J Case Rep. 2025;26:e948952.","journal-title":"Am J Case Rep"},{"issue":"26","key":"8736_CR5","doi-asserted-by":"publisher","first-page":"108308","DOI":"10.12998\/wjcc.v13.i26.108308","volume":"13","author":"LL Cheng","year":"2025","unstructured":"Cheng LL, Tang B, Liu H, Zhu F, Chen YF, Zhang W. Thoughts and challenges of giant retroperitoneal liposarcoma: A case report. World J Clin Cases. 2025;13(26):108308.","journal-title":"World J Clin Cases"},{"key":"8736_CR6","doi-asserted-by":"publisher","first-page":"103280","DOI":"10.1016\/j.eclinm.2025.103280","volume":"84","author":"F Tirotta","year":"2025","unstructured":"Tirotta F, Fiore M, Bonvalot S, et al. Defining benchmark values for outcomes of comprehensive resection of primary retroperitoneal liposarcoma: a retrospective multicenter study. EClinicalMedicine. 2025;84:103280.","journal-title":"EClinicalMedicine"},{"issue":"15","key":"8736_CR7","doi-asserted-by":"publisher","first-page":"e71129","DOI":"10.1002\/cam4.71129","volume":"14","author":"S Sun","year":"2025","unstructured":"Sun S, Cardona K, Tseng WW. Surgical Management of Retroperitoneal Liposarcoma: Opportunities for Multimodality Treatment, Including Systemic Therapy. Cancer Med. 2025;14(15):e71129.","journal-title":"Cancer Med"},{"key":"8736_CR8","doi-asserted-by":"publisher","first-page":"1529755","DOI":"10.3389\/fphar.2025.1529755","volume":"16","author":"H Liu","year":"2025","unstructured":"Liu H, Wang X, Wang X, Qiu F, Zhou B. Challenges and hope: latest research trends in the clinical treatment and prognosis of liposarcoma. Front Pharmacol. 2025;16:1529755. Published 2025 May 12.","journal-title":"Front Pharmacol"},{"issue":"1","key":"8736_CR9","doi-asserted-by":"publisher","first-page":"W37","DOI":"10.2214\/AJR.10.5824","volume":"197","author":"KN O\u2019Regan","year":"2011","unstructured":"O\u2019Regan KN, Jagannathan J, Krajewski K, et al. Imaging of liposarcoma: classification, patterns of tumor recurrence, and response to treatment. AJR Am J Roentgenol. 2011;197(1):W37\u201343.","journal-title":"AJR Am J Roentgenol"},{"issue":"4","key":"8736_CR10","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1002\/cam4.5298","volume":"12","author":"P Thirasastr","year":"2023","unstructured":"Thirasastr P, Lin H, Amini B, et al. Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcoma. Cancer Med. 2023;12(4):4282\u201393.","journal-title":"Cancer Med"},{"issue":"2","key":"8736_CR11","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s13691-024-00661-x","volume":"13","author":"K Nakajima","year":"2024","unstructured":"Nakajima K, Iwata H, Sudo S, et al. Spot scanning proton therapy for unresectable bulky retroperitoneal dedifferentiated liposarcoma: a case report. Int Cancer Conf J. 2024;13(2):171\u20136.","journal-title":"Int Cancer Conf J"},{"issue":"10","key":"8736_CR12","doi-asserted-by":"publisher","first-page":"e257056","DOI":"10.6004\/jnccn.2025.7056","volume":"23","author":"A Baudo","year":"2025","unstructured":"Baudo A, de Angelis M, Siech C, et al. Perioperative Radiotherapy and Survival After Surgical Treatment of Nonmetastatic Retroperitoneal Sarcoma. J Natl Compr Canc Netw. 2025;23(10):e257056.","journal-title":"J Natl Compr Canc Netw"},{"issue":"8","key":"8736_CR13","doi-asserted-by":"publisher","first-page":"103667","DOI":"10.1016\/j.esmoop.2024.103667","volume":"9","author":"C Fabbroni","year":"2024","unstructured":"Fabbroni C, Grignani G, Vincenzi B, et al. TRAbectedin in adVanced rEtroperitoneal well differentiated\/dedifferentiated Liposarcoma and Leiomyosarcoma (TRAVELL): results of a phase II study from the Italian Sarcoma Group. ESMO Open. 2024;9(8):103667.","journal-title":"ESMO Open"},{"issue":"43","key":"8736_CR14","doi-asserted-by":"publisher","first-page":"e06313","DOI":"10.1002\/advs.202506313","volume":"12","author":"M 14 Luo","year":"2025","unstructured":"14 Luo M, Liu J, Su Y, et al. Regulating PPARG Reduces Lipid Accumulation in Microglia and Promotes Functional Recovery After Spinal Cord Injury. Adv Sci (Weinh). 2025;12(43):e06313.","journal-title":"Adv Sci (Weinh)"},{"key":"8736_CR15","doi-asserted-by":"publisher","first-page":"108391","DOI":"10.1016\/j.pharmthera.2023.108391","volume":"245","author":"H Chen","year":"2023","unstructured":"Chen H, Tan H, Wan J, et al. PPAR-\u03b3 signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets. Pharmacol Ther. 2023;245:108391.","journal-title":"Pharmacol Ther"},{"issue":"12","key":"8736_CR16","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41569-021-00569-6","volume":"18","author":"D Montaigne","year":"2021","unstructured":"Montaigne D, Butruille L, Staels B. PPAR control of metabolism and cardiovascular functions. Nat Rev Cardiol. 2021;18(12):809\u201323.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"8736_CR17","doi-asserted-by":"publisher","first-page":"8215","DOI":"10.1038\/s41467-025-62710-0","volume":"16","author":"K Chang","year":"2025","unstructured":"Chang K, Delavan HM, Yip E, et al. Modulating the PPAR\u03b3 pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer. Nat Commun. 2025;16(1):8215.","journal-title":"Nat Commun"},{"issue":"5","key":"8736_CR18","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/FJC.0000000000001684","volume":"85","author":"CX Li","year":"2025","unstructured":"Li CX, Wu RM, Xie QL, Wang F, Xu XL. Procyanidin B2 Attenuates Pathologic Cardiac Fibrosis and Inflammation: Role of PPAR\u03b3. J Cardiovasc Pharmacol. 2025;85(5):338\u201349.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"5","key":"8736_CR19","doi-asserted-by":"publisher","first-page":"112167","DOI":"10.1016\/j.isci.2025.112167","volume":"28","author":"X Liu","year":"2025","unstructured":"Liu X, Qiu R, Gui P, et al. Osteoclast-derived arachidonic acid triggers dormant lung adenocarcinoma cell activation. iScience. 2025;28(5):112167.","journal-title":"iScience"},{"issue":"21","key":"8736_CR20","doi-asserted-by":"publisher","first-page":"5403","DOI":"10.1002\/cncr.27526","volume":"118","author":"MJ Pishvaian","year":"2012","unstructured":"Pishvaian MJ, Marshall JL, Wagner AJ, et al. A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies. Cancer. 2012;118(21):5403\u201313.","journal-title":"Cancer"},{"issue":"2","key":"8736_CR21","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3390\/cancers16020271","volume":"16","author":"EA Lesovaya","year":"2024","unstructured":"Lesovaya EA, Fetisov TI, Bokhyan BY, et al. Genetic, Epigenetic and Transcriptome Alterations in Liposarcoma for Target Therapy Selection. Cancers (Basel). 2024;16(2):271.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"8736_CR22","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY, et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22(1):138. Published 2023 Aug 18.","journal-title":"Mol Cancer"},{"key":"8736_CR23","doi-asserted-by":"publisher","first-page":"121417","DOI":"10.1016\/j.jep.2026.121417","volume":"363","author":"Y Hu","year":"2026","unstructured":"Hu Y, Wan Y, Lu Z, et al. Simo Tang mitigates mitochondria-dependent apoptosis via PI3K\/AKT pathway activation in Chronic atrophic gastritis. J Ethnopharmacol. 2026;363:121417.","journal-title":"J Ethnopharmacol"},{"issue":"2","key":"8736_CR24","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3390\/antiox15020173","volume":"15","author":"C Longobardi","year":"2026","unstructured":"Longobardi C, Lotito D, Staropoli A, et al. Natural Product Epipyrone A from Epicoccum nigrum Exhibits Antiproliferative Activity on Canine Mammary Tumor Cells Through PI3K\/AKT\/mTOR Pathway Modulation. Antioxid (Basel). 2026;15(2):173.","journal-title":"Antioxid (Basel)"},{"issue":"8","key":"8736_CR25","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.7150\/ijbs.89942","volume":"20","author":"F Fontana","year":"2024","unstructured":"Fontana F, Giannitti G, Marchesi S, Limonta P. The PI3K\/AKT Pathway and Glucose Metabolism: A Dangerous Liaison in Cancer. Int J Biol Sci. 2024;20(8):3113\u201325.","journal-title":"Int J Biol Sci"},{"key":"8736_CR26","doi-asserted-by":"crossref","unstructured":"Jiang M, Zhang K, Zhang Z, et al. PI3K\/AKT\/mTOR axis in cancer: from pathogenesis to treatment. MedComm (2020). 2025;6(8):e70295.","DOI":"10.1002\/mco2.70295"},{"key":"8736_CR27","unstructured":"Yoon C, Lu J, Yi BC, et al. PI3K\/AKT pathway and Nanog maintain cancer stem cells in sarcomas. Oncogenesis. [Retracted in: Oncogenesis. 2024 May 29;13(1):18.]"},{"issue":"1","key":"8736_CR28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41389-022-00394-7","volume":"11","author":"R Berthold","year":"2022","unstructured":"Berthold R, Isfort I, Erkut C, et al. Fusion protein-driven IGF-IR\/PI3K\/AKT signals deregulate Hippo pathway promoting oncogenic cooperation of YAP1 and FUS-DDIT3 in myxoid liposarcoma. Oncogenesis. 2022;11(1):20.","journal-title":"Oncogenesis"},{"issue":"2","key":"8736_CR29","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1158\/1535-7163.MCT-14-0711","volume":"14","author":"EK Slotkin","year":"2015","unstructured":"Slotkin EK, Patwardhan PP, Vasudeva SD, de Stanchina E, Tap WD, Schwartz GK. MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma. Mol Cancer Ther. 2015;14(2):395\u2013406.","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"8736_CR30","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1158\/1535-7163.MCT-18-0763","volume":"18","author":"M Trautmann","year":"2019","unstructured":"Trautmann M, Cyra M, Isfort I, et al. Phosphatidylinositol-3-kinase (PI3K)\/AKT Signaling is Functionally Essential in Myxoid Liposarcoma. Mol Cancer Ther. 2019;18(4):834\u201344.","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"8736_CR31","doi-asserted-by":"publisher","first-page":"6255","DOI":"10.3892\/mmr.2015.4224","volume":"12","author":"Y Li","year":"2015","unstructured":"Li Y, Zhang DW, Lin DQ, Cao LQ. Peroxisome proliferator-activated receptor-\u03b3 inhibits pancreatic cancer cell invasion and metastasis via regulating MMP-2 expression through PTEN. Mol Med Rep. 2015;12(4):6255\u201360.","journal-title":"Mol Med Rep"},{"key":"8736_CR32","doi-asserted-by":"publisher","first-page":"2271214","DOI":"10.1155\/2024\/2271214","volume":"2024","author":"B Han","year":"2024","unstructured":"Han B, Chen J, Chen S, et al. PPARG and the PTEN-PI3K\/AKT Signaling Axis May Cofunction in Promoting Chemosensitivity in Hypopharyngeal Squamous Cell Carcinoma. PPAR Res. 2024;2024:2271214.","journal-title":"PPAR Res"},{"key":"8736_CR33","doi-asserted-by":"publisher","first-page":"958443","DOI":"10.3389\/fphar.2022.958443","volume":"13","author":"U Mehraj","year":"2022","unstructured":"Mehraj U, Wani NA, Hamid A, Alkhanani M, Almilaibary A, Mir MA. Adapalene inhibits the growth of triple-negative breast cancer cells by S-phase arrest and potentiates the antitumor efficacy of GDC-0941. Front Pharmacol. 2022;13:958443.","journal-title":"Front Pharmacol"},{"issue":"2","key":"8736_CR34","doi-asserted-by":"publisher","first-page":"462","DOI":"10.3390\/cancers15020462","volume":"15","author":"H Kikuchi","year":"2023","unstructured":"Kikuchi H, Amofa E, Mcenery M, et al. Inhibition of PI3K Class IA Kinases Using GDC-0941 Overcomes Cytoprotection of Multiple Myeloma Cells in the Osteoclastic Bone Marrow Microenvironment Enhancing the Efficacy of Current Clinical Therapeutics. Cancers (Basel). 2023;15(2):462.","journal-title":"Cancers (Basel)"},{"issue":"13","key":"8736_CR35","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1056\/NEJM199803263381311","volume":"338","author":"H Imura","year":"1998","unstructured":"Imura H. A novel antidiabetic drug, troglitazone\u2013reason for hope and concern. N Engl J Med. 1998;338(13):908\u20139.","journal-title":"N Engl J Med"},{"issue":"11","key":"8736_CR36","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.2337\/dc18-1079","volume":"41","author":"MD DeBoer","year":"2018","unstructured":"DeBoer MD, Filipp SL, Gurka MJ. Use of a Metabolic Syndrome Severity Z Score to Track Risk During Treatment of Prediabetes: An Analysis of the Diabetes Prevention Program. Diabetes Care. 2018;41(11):2421\u201330.","journal-title":"Diabetes Care"},{"issue":"3","key":"8736_CR37","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3390\/pharmaceutics13030315","volume":"13","author":"K Kores","year":"2021","unstructured":"Kores K, Konc J, Bren U. Mechanistic Insights into Side Effects of Troglitazone and Rosiglitazone Using a Novel Inverse Molecular Docking Protocol. Pharmaceutics. 2021;13(3):315.","journal-title":"Pharmaceutics"},{"issue":"1","key":"8736_CR38","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13046-017-0557-6","volume":"36","author":"M Fujita","year":"2017","unstructured":"Fujita M, Hasegawa A, Yamamori M, Okamura N. In vitro and in vivo cytotoxicity of troglitazone in pancreatic cancer. J Exp Clin Cancer Res. 2017;36(1):91.","journal-title":"J Exp Clin Cancer Res"},{"issue":"16","key":"8736_CR39","doi-asserted-by":"publisher","first-page":"26819","DOI":"10.18632\/oncotarget.15819","volume":"8","author":"UM Nazim","year":"2017","unstructured":"Nazim UM, Moon JH, Lee YJ, Seol JW, Park SY. PPAR\u03b3 activation by troglitazone enhances human lung cancer cells to TRAIL-induced apoptosis via autophagy flux. Oncotarget. 2017;8(16):26819\u201331.","journal-title":"Oncotarget"},{"issue":"47","key":"8736_CR40","doi-asserted-by":"publisher","first-page":"82491","DOI":"10.18632\/oncotarget.19700","volume":"8","author":"ANH Phan","year":"2017","unstructured":"Phan ANH, Vo VTA, Hua TNM, et al. PPAR\u03b3 sumoylation-mediated lipid accumulation in lung cancer. Oncotarget. 2017;8(47):82491\u2013505.","journal-title":"Oncotarget"},{"issue":"11","key":"8736_CR41","doi-asserted-by":"publisher","first-page":"e70227","DOI":"10.1111\/1751-7915.70227","volume":"18","author":"Y Gao","year":"2025","unstructured":"Gao Y, Zhu A, Li J, Liu H, Li X, Zhang H. Lactiplantibacillus plantarum Attenuates Diet-Induced Obesity and Insulin Resistance Through Gut Microbiota-Driven PPAR\/PI3K-Axis Modulation. Microb Biotechnol. 2025;18(11):e70227.","journal-title":"Microb Biotechnol"},{"issue":"1","key":"8736_CR42","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12957-023-03295-0","volume":"22","author":"C Zhou","year":"2024","unstructured":"Zhou C, Li M, Ren Y, et al. Immune characteristics of dedifferentiated retroperitoneal liposarcomas and the reliability of regional samples in evaluating their tumor immune microenvironments. World J Surg Oncol. 2024;22(1):25.","journal-title":"World J Surg Oncol"},{"issue":"1","key":"8736_CR43","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12957-024-03552-w","volume":"22","author":"Y Yamada","year":"2024","unstructured":"Yamada Y, Wakamatsu T, Imura Y, et al. Efficacy of surgery in the management of multiple recurrences of retroperitoneal dedifferentiated liposarcoma. World J Surg Oncol. 2024;22(1):265.","journal-title":"World J Surg Oncol"},{"issue":"1","key":"8736_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11864-018-0520-6","volume":"19","author":"SA Mansfield","year":"2018","unstructured":"Mansfield SA, Pollock RE, Grignol VP. Surgery for Abdominal Well-Differentiated Liposarcoma. Curr Treat Options Oncol. 2018;19(1):1.","journal-title":"Curr Treat Options Oncol"},{"issue":"6","key":"8736_CR45","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S0300-2896(15)30758-4","volume":"32","author":"JN Alcal\u00e1 Pedrajas","year":"1996","unstructured":"Alcal\u00e1 Pedrajas JN, Jim\u00e9nez Murillo L, Clemente Mill\u00e1n MJ. Liposarcoma retroperitoneal con met\u00e1stasis pulmonares, cut\u00e1neas y pancre\u00e1ticas [Retroperitoneal liposarcoma with lung, skin and pancreatic metastases]. Arch Bronconeumol. 1996;32(6):313\u20135.","journal-title":"Arch Bronconeumol"},{"issue":"1","key":"8736_CR46","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/jso.24929","volume":"117","author":"SP Bagaria","year":"2018","unstructured":"Bagaria SP, Gabriel E, Mann GN. Multiply recurrent retroperitoneal liposarcoma. J Surg Oncol. 2018;117(1):62\u20138.","journal-title":"J Surg Oncol"},{"key":"8736_CR47","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2147\/OTT.S72722","volume":"8","author":"Z Guan","year":"2015","unstructured":"Guan Z, Yu X, Wang H, et al. Advances in the targeted therapy of liposarcoma. Onco Targets Ther. 2015;8:125\u201336.","journal-title":"Onco Targets Ther"},{"issue":"15","key":"8736_CR48","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1158\/1078-0432.CCR-22-0518","volume":"28","author":"CG Kim","year":"2022","unstructured":"Kim CG, Sim NS, Kim JE, et al. Phase II Clinical Trial of Eribulin-Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma. Clin Cancer Res. 2022;28(15):3225\u201334.","journal-title":"Clin Cancer Res"},{"key":"8736_CR49","doi-asserted-by":"publisher","first-page":"857827","DOI":"10.3389\/fonc.2022.857827","volume":"12","author":"Y Li","year":"2022","unstructured":"Li Y, Wu G, Zhang Y, et al. Development and Validation of a Prognostic Model to Predict the Prognosis of Patients With Retroperitoneal Liposarcoma: A Large International Population-Based Cohort Study. Front Oncol. 2022;12:857827.","journal-title":"Front Oncol"},{"issue":"13","key":"8736_CR50","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1056\/NEJM199803263381314","volume":"338","author":"PB Watkins","year":"1998","unstructured":"Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med. 1998;338(13):916\u20137.","journal-title":"N Engl J Med"},{"issue":"1","key":"8736_CR51","doi-asserted-by":"publisher","first-page":"128","DOI":"10.2337\/diacare.23.1.128","volume":"23","author":"DS Bell","year":"2000","unstructured":"Bell DS, Ovalle F. Late-onset troglitazone-induced hepatic dysfunction. Diabetes Care. 2000;23(1):128\u20139.","journal-title":"Diabetes Care"},{"issue":"2","key":"8736_CR52","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3390\/biomedicines14020418","volume":"14","author":"A Harangu\u0219","year":"2026","unstructured":"Harangu\u0219 A, Chi\u0219 IC, Clichici SV, et al. Comparative Evaluation of Quercetin, Pioglitazone, Insulin, and Novel 5-Chromenyl-Methylene Thiazolidinedione Derivative on Nerve Function in Experimental Diabetic Peripheral Neuropathy. Biomedicines. 2026;14(2):418.","journal-title":"Biomedicines"},{"issue":"1","key":"8736_CR53","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s00280-025-04855-9","volume":"96","author":"Y Katsuya","year":"2026","unstructured":"Katsuya Y, Takenaka S, Takahashi S, Yamamoto N. Drug-drug interactions with pioglitazone, losartan, and midazolam and anti-tumor efficacy and safety study of TAS-115 in patients with solid tumors. Cancer Chemother Pharmacol. 2026;96(1):14.","journal-title":"Cancer Chemother Pharmacol"},{"key":"8736_CR54","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.canlet.2020.02.042","volume":"478","author":"B Choi","year":"2020","unstructured":"Choi B, Lee JS, Kim SJ, Hong D, Park JB, Lee KY. Anti-tumor effects of anti-PD-1 antibody, pembrolizumab, in humanized NSG PDX mice xenografted with dedifferentiated liposarcoma. Cancer Lett. 2020;478:56\u201369.","journal-title":"Cancer Lett"},{"issue":"5","key":"8736_CR55","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1039\/D5TB01845E","volume":"14","author":"J Wang","year":"2026","unstructured":"Wang J, Peng Y, Miao T, et al. A 3D bioprinted liposarcoma tumor microenvironment model recapitulates stroma-driven invasion and chemoresistance. J Mater Chem B. 2026;14(5):1522\u201336.","journal-title":"J Mater Chem B"},{"issue":"6","key":"8736_CR56","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41419-019-1658-2","volume":"10","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Tong H, He J, et al. Linc00423 as a tumor suppressor in retroperitoneal liposarcoma via activating MAPK signaling pathway through destabilizing of NFATC3. Cell Death Dis. 2019;10(6):430.","journal-title":"Cell Death Dis"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08736-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08736-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08736-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:12:41Z","timestamp":1788275561000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08736-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8736"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08736-4","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"21 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All experimental procedures involving animals and human\u2011derived materials were performed in strict accordance with relevant guidelines and regulations. Animal study protocols were reviewed and approved by the Animal Ethics Committee of Air Force Medical University (Approval No. 20250142). The use of human tissue samples, clinical data, and all related experimental procedures were approved by the Ethics Committee of Xijing Hospital (Approval No. XJLL\u2011KY\u20112025237). Written informed consent was obtained from all patients.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have read the manuscript and provided their consent for the submission.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1124"}}